Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis

Dataset of mRNA levels for dopaminergic receptors, adrenoceptors and tyrosine hydroxylase in lymphocytes from subjects with clinically isolated syndromes

“…Cells were obtained from venous blood of CIS subjects enrolled at the Centre for research on Multiple Sclerosis, Ospedale S. Antonio Abate of Gallarate (VA) (Investigator in charge: Mauro Zaffaroni), at the Neurology Unit of the “Ospedale di Circolo e Fondazione Macchi”, University of Insubria - School of Medicine of Varese (Investigator in charge: Giorgio Bono), and at the Neurological Department, Valduce Hospital, Como (Investigator in charge: Mario Guidotti). Inclusion and exclusion criteria for selection and enrollement of CIS subjects, as well as criteria to define conversion of CIS to MS are detailed elsewhere [1] . Approval of the protocol was obtained from the Ethics Committee of the Ospedale S. Antonio Abate of Gallarate (VA), and all the participants provided a written informed consent.…”

“…Enclosed are data regarding mRNA levels for dopaminergic receptors (DR), adrenoceptors (AR) and tyrosine hydroxylase (TH), the rate-limiting enzyme in the synthesis of catecholamines, found in peripheral blood mononuclear cells (PBMC) ( Table 1 , Table 2 ) and in CD4+ T effector (Teff) cells ( Table 3 ) and regulatory (Treg) cells ( Table 4 ) from subjects with clinically isolated syndromes (CIS), which is a first, usually recovering, episode of neurological disturbance(s) suggestive of multiple sclerosis (MS). Each table provides a comparison between subjects who, after 12 months from CIS, did not progress or progressed to clinically established MS. For further information and discussion about the interpretation and implications of DR, AR and TH mRNA levels in lymphocytes of CIS subjects, please refer to the article [1] .…”

“…CIS subjects are divided into two groups according to their eventual progression, after 12 months from CIS, to clinically established multiple sclerosis. The data reported are related to the article entitled "Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis" (M. Cosentino, M. Zaffaroni, M. Legnaro, R. Bombelli, L. Schembri, D. Baroncini, A. Bianchi, R. Clerici, M. Guidotti, P. Banfi, G. Bono, F. Marino, 2016) [1] .…”

β2-Adrenoceptors inhibit neutrophil extracellular traps in human polymorphonuclear leukocytes

“…CA can modulate hematopoiesis and their content in immune cells is affected by several diseases; cells of acquired and innate immunity express both adrenergic receptors (AR) and dopaminergic receptors (DR) and it has been shown that the activation of these receptors results in changes of different cell functions . Several studies have shown that these receptors are involved in immune‐mediated diseases …”

“…19,[24][25][26][27] Several studies have shown that these receptors are involved in immunemediated diseases. 23,28,29 We have previously shown that, during activation with proinflammatory stimuli, human PMN undergo morphological and functional changes, [30][31][32][33][34][35] including changes in AR expression. 27 We have also shown that these changes are followed by increased production of chemokines, such as IL-8, 30,31 and increased generation of ROS.…”